Dexelvucitabine

Dexelvucitabine is a failed experimental agent for the management of HIV infection. Dexelvucitabine is a cytidine nucleoside analog and nucleoside reverse transcriptase inhibitor. It was found to inhibit HIV-1 replication in vitro and during Phase II clinical trials, it was found to decrease mean viral load in patients with HIV.

Dexelvucitabine

Names
IUPAC name 4-Amino-5-fluoro-1-[(2R,5S)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]pyrimidin-2-one
Other names Reverset
Identifiers
CAS Number	134379-77-4
3D model (JSmol)	Interactive image
ChEMBL	ChEMBL109831
ChemSpider	58498
KEGG	D03981
PubChem CID	64973
UNII	KU8SPJ271W
CompTox Dashboard (EPA)	DTXSID20158678
InChI InChI=1S/C9H10FN3O3/c10-6-3-13(9(15)12-8(6)11)7-2-1-5(4-14)16-7/h1-3,5,7,14H,4H2,(H2,11,12,15)/t5-,7+/m0/s1 Key: HSBKFSPNDWWPSL-CAHLUQPWSA-N InChI=1/C9H10FN3O3/c10-6-3-13(9(15)12-8(6)11)7-2-1-5(4-14)16-7/h1-3,5,7,14H,4H2,(H2,11,12,15)/t5-,7+/m0/s1 Key: HSBKFSPNDWWPSL-CAHLUQPWBD
SMILES F\C1=C\N(C(=O)\N=C1\N)[C@@H]/2O[C@@H](\C=C\2)CO
Properties
Chemical formula	C9H10FN3O3
Molar mass	227.195 g·mol^−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
verify (what is  ?)
Infobox references

On April 3, 2006, Pharmasset and Incyte, the pharmaceutical companies developing dexelvucitabine announced the decision to cease further trials and development of the drug due to an increased incidence of grade 4 hyperlipasemia (an excess of the pancreatic enzyme, lipase) in a phase II trial.